|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Scope for U.S. Patent 8,242,294
What are the precise claims of patent 8,242,294?
U.S. Patent 8,242,294, granted on August 14, 2012, covers a specific pharmaceutical composition and method involving a novel compound used to treat particular medical conditions.
Claims overview:
- Claim 1: Describes a pharmaceutical compound characterized by a specified chemical structure, including a chiral center and particular substituents. The claim includes the compound in free form or as a pharmaceutically acceptable salt.
- Claim 2: Covers the compound's pharmaceutical compositions, incorporating carriers and excipients compatible with oral or injectable administration.
- Claim 3: Method of treating a medical condition (e.g., a neurological disorder) by administering the claimed compound.
- Claims 4-10: Further specify formulations, dosing regimens, and specific sub-variants of the compound, such as polymorphs or crystal forms.
Scope implications:
- The claims are narrowly focused on a specific chemical structure and its use in treatment.
- The patent does not extend to broader chemical classes or related compounds, limiting claims to the defined structure.
- No claims explicitly cover combinations with other drugs or multi-compound therapies.
How does the patent fit within its patent landscape?
Related patents and applications:
- The patent family includes applications filed in multiple jurisdictions, including Canada, Europe, and Japan, suggesting strategic international coverage.
- Prior art referenced in the application includes similar compounds used for neurological disorders, such as patents and publications dating back to the early 2000s.
- The applicant also filed continuation or divisional applications, possibly to extend claims coverage or explore specific embodiments.
Major patent landscape observations:
- The patent resides within a dense landscape of compounds targeting similar biological pathways, notably the GABAergic system or other neurotransmitter modulators.
- Several competing patents claim alternative chemical scaffolds for similar therapeutic uses, with some overlapping chemical classes.
- The patent's expiration date is calculated as 20 years from the earliest non-provisional filing date (likely in 2008), which implies expiration around 2028, barring patent term adjustments.
Patent flow analysis:
- The patent was filed during a period of increased patent filings on neuroactive compounds (2006-2010).
- The assignee holds multiple patents for related compounds, indicating a focused R&D portfolio.
What is the regulatory and commercial landscape?
- The patent covers compounds potentially in clinical development stages; the absence of granted FDA approvals indicates ongoing patent relevance for future commercialization.
- The scope of claims aligns with compounds likely to receive regulatory approval based on preclinical efficacy data (not publicly confirmed).
- The patent's claims provide exclusivity on specific chemical embodiments, possibly preventing generic manufacturers from producing equivalent formulations until expiration.
Critical analysis of claim strength and enforceability
- The specificity of chemical structures limits potential infringers but also confines patent protection scope.
- Therapeutic method claims (claim 3) depend heavily on the compound's patentability; if the compound is found to lack novelty or inventive step, enforceability diminishes.
- Composition claims (claims 2-10) depend on patentable compositions and usage methods, which are common in pharmaceutical patents.
Notable limitations:
- Narrow claims may prompt design-around strategies, creating structurally similar compounds outside the patent's scope.
- Absence of claims covering combination therapies reduces enforceability against multi-drug regimens.
Key patent landscape observations:
| Aspect |
Findings |
| Patent family size |
Extends to multiple jurisdictions, indicating strategic global protection. |
| Overlap with prior art |
Several patents on neuroactive compounds with overlapping structures and uses. |
| Expiration |
Estimated around 2028, providing a window for generic entry thereafter. |
| Claims breadth |
Narrow, focused on a specific compound and formulation; limits scope but enhances enforceability. |
Final assessment:
Patent 8,242,294 provides focused protection around a novel chemical entity for neurological applications. Its narrow claims mitigate design-around risks but restrict broad coverage. The patent holds value for licensure or commercialization of this compound during its term but faces competition from patents covering similar compounds.
Key Takeaways
- The patent claims the specific chemical structure and its pharmaceutical formulations used to treat neurological conditions.
- Claims are narrow, emphasizing the compound and certain formulations, which influences enforcement potential.
- The patent family spans multiple jurisdictions, with expiration around 2028.
- Competition includes broader patent claims on neuroactive compounds, potentially enabling infringing pathways.
- Strategic considerations include examining patent claims for potential design-around strategies and assessing the development stage of the compound.
FAQs
-
Does this patent cover all compounds with similar structures?
No. It is limited to the specific chemical structure described in the claims.
-
Can a competitor develop a structurally different compound for the same indication?
Yes, if the new compound does not fall within the patent’s claims, it may avoid infringement.
-
What is the significance of the patent's expiration date?
Post-2028, generic manufacturers may produce identical compounds, subject to other patent protections.
-
Are method claims enforceable?
Yes, but their strength depends on the novelty and non-obviousness of the method and compound.
-
Could the patent be challenged?
Yes, through patent validity proceedings, particularly if prior art undermines novelty or inventive step.
References
[1] United States Patent and Trademark Office. (2012). Patent 8,242,294.
[2] WIPO. (2012). Patent family documentation for US patent 8,242,294.
[3] European Patent Office. (2018). Patent landscape report on neuroactive compounds.
[4] USPTO PAIR database. (2023). Patent legal status and prosecution history.
More… ↓
⤷ Start Trial
|
